The idea for the PBPK Conference 2026 started as a simple but powerful dream: to create an international conference dedicated entirely to the science of PBPK. A place where scientists can come together and focus solely on the latest advances, challenges, and opportunities in PBPK modelling without the limitations of being just a small track in a broader conference.
We are an interdisciplinary team brought together by our shared passion for PBPK. We believe deeply in the power of PBPK to inform better science, smarter decisions, and ultimately, improved outcomes for patients and society. What unites us is not only a love for the science, but a commitment to supporting it, advancing it, and creating space for it to thrive.
This conference is our way of giving PBPK the attention it deserves: its own forum for in-depth exchange, honest dialogue, and community building. We want to foster an environment where science leads, ideas are shared freely, and all voices whether emerging or established are heard.
What is PBPK?
Physiologically-Based Pharmacokinetic (PBPK) modelling is a computational modelling technique that predicts the absorption, distribution, metabolism, and excretion (ADME) of drugs and chemicals in the body using mathematical representations of human (or animal) physiology. Unlike traditional compartmental models, PBPK models are built on anatomically and physiologically realistic structures, incorporating organ-specific blood flow, tissue composition, enzyme expression, and transport mechanisms.
By integrating drug-specific properties (such as solubility, permeability, and metabolic pathways) with biological system data, PBPK models can simulate how a compound behaves across different populations from healthy adults to children, the elderly, patients with organ impairment, or specific ethnic groups. They can also account for drug-drug interactions, formulation effects, route of administration, and species differences in preclinical development.
PBPK modelling has rapidly evolved into a central tool in drug development and regulatory science. It is used to:
- Predict human pharmacokinetics based on in vitro and preclinical data
- Optimize dose selection and trial design
- Assess scenarios where clinical studies are unethical or impractical
- Support regulatory submissions and labelling decisions
- Explore mechanistic causes of observed clinical outcomes
Regulatory agencies around the world, including the FDA, EMA, PMDA, and others, have increasingly embraced PBPK modeling as part of model-informed drug development (MIDD), offering guidance on its use in areas such as first-in-human dosing, pediatric extrapolation, and bioequivalence assessment.
As the field continues to grow, PBPK modelling sits at the intersection of pharmacology, systems biology, mathematics, and data science. It represents not just a method, but a scientific framework — one that allows for quantitative, mechanism-based understanding of drug behaviour in complex biological systems.
At its core, PBPK is about making better-informed decisions by combining science, data, and modelling. That’s why this conference exists: to advance the science, foster collaboration, and ensure the PBPK community has a place to grow — together.
PBPK Conference 2026 